BioVie Achieved Alignment With The FDA On Its Upcoming SUNRISE-PD Trial In Parkinson's Disease. As A Result, The Company Is Conducting Trial Start-up Activities With A View To Initiate Patient Screening In Q4 2024
BioVie Achieved Alignment With The FDA On Its Upcoming SUNRISE-PD Trial In Parkinson's Disease. As A Result, The Company Is Conducting Trial Start-up Activities With A View To Initiate Patient Screening In Q4 2024
biovie已經與FDA就即將展開的SUNRISE-PD帕金森病試驗達成了一致意見。因此，該公司正在進行試驗啓動活動，旨在在2024年第四季度開始進行患者篩選。
- SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's disease who are naïve to carbidopa/levodopa.
- Company engaged in trial start-up activities and plans to initiate patient screening Q4 2024
- SUNRISE-PD 將評估 bezisterim（NE3107）在大約60名對卡必多巴/左旋多巴藥物無任何接觸的帕金森病患者的運動和非運動症狀上的效果。
- 公司正參與試驗開展活動，並計劃在2024年Q4啓動患者篩選。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。